Iovance Biotherapeutics Reports Q3 2026 Record Revenue Driven by AMTAGVI Growth
Iovance Biotherapeutics (IOVA) reported strong third-quarter 2026 financial results, highlighted by a total revenue of $121.5 million, representing an 80% increase compared to the same period in 2025. This growth was primarily fueled by AMTAGVI, which generated $101.5 million in revenue due to rising patient demand and increased adoption. The company also achieved a record gross margin of 60%, marking its second consecutive quarter at such levels through cost optimization and sales volume increases. Beyond financial performance, Iovance reached a significant milestone with over 1,000 commercial patient infusions in the U.S. Clinical developments remain robust, including positive response rates in lung cancer (IOV-LUN-202) and melanoma trials. With $382.3 million in cash expected to fund operations into 2029 and a reaffirmed full-year revenue guidance of $410 million to $420 million, the company is demonstrating significant operational scaling.
Topics: AMTAGVI Sales Financial Guidance Gross Margin Revenue Growth